Not Yet Recruiting PHASE2 INTERVENTIONAL 4-arm NCT06514027

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

A Multicenter, Open Phase II Clinical Study on the Safety and Efficacy of BEBT-109 Combined With Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Sponsor: BeBetter Med Inc

Conditions Non Small Cell Lung Cancer

Interventions BEBT-109 Capsules Carboplatin Injection Cisplatin Injection Pemetrexed Disodium for Injection

Updated 2 times since 2024 Last updated: Jul 17, 2024 Started: Jul 31, 2024 Primary completion: Jun 30, 2027 Completion: Nov 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non Small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by BeBetter Med Inc and has accumulated 2 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

2 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jul 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeBetter Med Inc

Data source: BeBetter Med Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China